{"entity":{"id":"nct05384587","kind":"trial","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","aka":[],"tldr":"A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT05384587 by Novartis Pharmaceuticals, with 34 participants enrolled, started 2022-11-11 and due to reach its primary completion in 2025-08-13. Interventions recorded: asciminib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05384587","url":"https://clinicaltrials.gov/study/NCT05384587"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["asciminib"],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05384587","phase":"2","setting":"A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)","sponsor":"Novartis Pharmaceuticals","enrolled":34,"outcomes":[]},"route":"/trials/nct05384587/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}